ClinicalTrials.gg
CompletedNCT00652301Updated Aug 15, 2024

A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)

A Phase 3 interventional study of ezetimibe and Comparator: Placebo (unspecified) in Cholesterol, sponsored by Organon and Co. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Organon and Co · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

To determine the effect of ezetimibe and simvastatin given together, and ezetimibe and simvastatin given alone on intestinal cholesterol absorption.

Read the detailed description

Patients will be randomized into 1 of 4 treatment sequences involving 4 consecutive 7-week treatment periods.

02

Conditions studied

  • Cholesterol
03

In context

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males between the ages of 18-55 with LDL More than 130, but less than 180

Exclusion criteria

Exclusion Criteria:

  • Individuals with drug or substance abuse
  • Individuals with poor mental function
  • Individuals having more than 14 alcoholic drinks a week
  • Individuals that have been treated with any other drug in the last 30 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    1

    ezetimibe 10 mg tablet plus simvastatin 20 mg tablet

    Drug: ezetimibe · Drug: simvastatin

  • Active comparator
    2

    ezetimibe 10 mg tablet

    Drug: ezetimibe · Drug: Comparator: Placebo (unspecified)

  • Active comparator
    3

    simvastatin 20 mg tablet

    Drug: Comparator: Placebo (unspecified) · Drug: simvastatin

  • Placebo comparator
    4

    matching placebo

    Drug: Comparator: Placebo (unspecified)

Interventions

  • ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.

    Also known as: MK0653

  • DrugComparator: Placebo (unspecified)

    matching placebo tablet. Duration of Treatment 31 Weeks.

  • simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.

    Also known as: MK0733

06

What researchers measure

Primary outcomes

  1. reduced intestinal cholesterol absorption with ezetimibe + simvastatin vs simvastatin alone.

    Time frame: Based on 7 week treatment periods.

Secondary outcomes

  1. To determine the effects of ezetimibe alone and simvastatin alone on intestinal cholesterol absorption.

    Time frame: Based on 7 week treatment periods.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Sudhop T, Reber M, Tribble D, Sapre A, Taggart W, Gibbons P, Musliner T, von Bergmann K, Lutjohann D. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res. 2009 Oct;50(10):2117-23. doi: 10.1194/jlr.P900004-JLR200. Epub 2009 Apr 20. PubMed 19380898 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Apr 2004 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2008
First posted
Apr 3, 2008
Start
Jul 2003
Primary completionActual
Apr 2004
CompletionActual
Apr 2004
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00652301
Lead sponsor
Organon and Co
Collaborators
Schering-Plough
Responsible party
Sponsor
First posted
Apr 3, 2008
Start date
Jul 2003
Primary completion
Apr 2004
Completion
Apr 2004
Last update
Aug 15, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Simvastatin

Start the discussion